Article

A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant Tumors

2024-06-04

Abstract excerpt

<title>Abstract</title> <p>ER<sup>+</sup> breast cancer (BC) patients frequently develop drug resistance during the treatment with endocrine therapy (ET). One of the mechanisms for drug resistance is acquired <italic>ESR1</italic> mutations. Thus, developing effective new ET overcoming drug resistance is urgently needed. We disclose herein TFX06, a novel and oral selective estrogen receptor degrader. TFX06 exhibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 07a9dc98-01df-5243-b058-b444986c0e89
DOI: 10.21203/rs.3.rs-4417562/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant TumorsDOI 10.21203/rs.3.rs-4417562/v1Read

Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast CancerSemantic proximity Read

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.Semantic proximity Read

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.Semantic proximity Read

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In VivoSemantic proximity Read

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) effectively shrinks tumors both in intracranial and subcutaneous ER+ breast cancer modelsSemantic proximity Read

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.Semantic proximity Read

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Semantic proximity Read

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.Semantic proximity Read

Overview of the therapeutic strategies for ER positive breast cancer.Semantic proximity Read